These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 7543022)

  • 1. Induction of tumor-specific T lymphocyte responses in vivo by prothymosin alpha.
    Baxevanis CN; Gritzapis AD; Spanakos G; Tsitsilonis OE; Papamichail M
    Cancer Immunol Immunother; 1995 Jun; 40(6):410-8. PubMed ID: 7543022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of lymphokine-activated killer activity in mice by prothymosin alpha.
    Baxevanis CN; Gritzapis AD; Dedoussis GV; Papadopoulos NG; Tsolas O; Papamichail M
    Cancer Immunol Immunother; 1994 Apr; 38(4):281-6. PubMed ID: 8168124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Promotion of murine antitumor activity by prothymosin alpha treatment: I. Induction of tumoricidal peritoneal cells producing high levels of tumour necrosis factor alpha.
    Papanastasiou M; Baxevanis CN; Papamichail M
    Cancer Immunol Immunother; 1992; 35(2):145-50. PubMed ID: 1596938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergy between interleukin-2 and prothymosin alpha for the increased generation of cytotoxic T lymphocytes against autologous human carcinomas.
    Voutsas IF; Baxevanis CN; Gritzapis AD; Missitzis I; Stathopoulos GP; Archodakis G; Banis C; Voelter W; Papamichail M
    Cancer Immunol Immunother; 2000 Oct; 49(8):449-58. PubMed ID: 11043852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alloantigen-induced cytotoxicity against syngeneic tumor cells: analysis at the clonal level.
    Sensi M; Orosz CG; Bach FH
    J Immunol; 1984 Jun; 132(6):3218-25. PubMed ID: 6202778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effector cells of low-dose IL-2 immunotherapy in tumor bearing mice: tumor cell killing by CD8+ cytotoxic T lymphocytes and macrophages.
    Maas RA; Roest PA; Becker MJ; Weimar IS; Dullens HF; Den Otter W
    Immunobiology; 1992 Nov; 186(3-4):214-29. PubMed ID: 1490728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD4-CD8- T cell receptor alpha beta T cells: generation of an in vitro major histocompatibility complex class I specific cytotoxic T lymphocyte response and allogeneic tumor rejection.
    Mieno M; Suto R; Obata Y; Udono H; Takahashi T; Shiku H; Nakayama E
    J Exp Med; 1991 Jul; 174(1):193-201. PubMed ID: 1905338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction and characterization of minor histocompatibility antigens. Specific primary cytotoxic T lymphocyte responses in vitro.
    Ando K; Nakashima I; Nagase F; Isobe K; Kawashima K; Hasegawa Y; Yoshida T; Iwamoto T; Hasegawa T; Muro Y
    J Immunol; 1988 Feb; 140(3):723-9. PubMed ID: 2448374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. B7-1 but not B7-2 efficiently costimulates CD8+ T lymphocytes in the P815 tumor system in vitro.
    Gajewski TF
    J Immunol; 1996 Jan; 156(2):465-72. PubMed ID: 8543795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-2 killer cells: in vitro evaluation of combination with prothymosin alpha.
    López-Rodríguez JL; Cordero OJ; Sarandeses C; Viñuela J; Nogueira M
    Lymphokine Cytokine Res; 1994 Jun; 13(3):175-82. PubMed ID: 7948426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor-specific CD4+ T lymphocytes from cancer patients are required for optimal induction of cytotoxic T cells against the autologous tumor.
    Baxevanis CN; Voutsas IF; Tsitsilonis OE; Gritzapis AD; Sotiriadou R; Papamichail M
    J Immunol; 2000 Apr; 164(7):3902-12. PubMed ID: 10725753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of overlapping epitopes in mutant ras oncogene peptides that activate CD4+ and CD8+ T cell responses.
    Abrams SI; Stanziale SF; Lunin SD; Zaremba S; Schlom J
    Eur J Immunol; 1996 Feb; 26(2):435-43. PubMed ID: 8617315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of Meth A sarcoma-derived class I major histocompatibility complex-associated peptides recognized by a specific CD8+ cytotoxic T lymphocyte.
    Frassanito MA; Mayordomo JI; DeLeo RM; Storkus WJ; Lotze MT; DeLeo AB
    Cancer Res; 1995 Jan; 55(1):124-8. PubMed ID: 7528638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of TC-1 cytokine production, effector cytotoxic T lymphocyte development and alloantibody production by 2,3,7,8-tetrachlorodibenzo-p-dioxin.
    Kerkvliet NI; Baecher-Steppan L; Shepherd DM; Oughton JA; Vorderstrasse BA; DeKrey GK
    J Immunol; 1996 Sep; 157(6):2310-9. PubMed ID: 8805628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prothymosin α and a prothymosin α-derived peptide enhance T(H)1-type immune responses against defined HER-2/neu epitopes.
    Ioannou K; Derhovanessian E; Tsakiri E; Samara P; Kalbacher H; Voelter W; Trougakos IP; Pawelec G; Tsitsilonis OE
    BMC Immunol; 2013 Sep; 14():43. PubMed ID: 24053720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The presence and cytotoxicity of CD16+ CD2- subset from PBL and NK cells in long-term IL-2 cultures enhanced by Prothymosin-alpha.
    Cordero OJ; Sarandeses C; López-Rodríguez JL; Nogueira M
    Immunopharmacology; 1995 Apr; 29(3):215-23. PubMed ID: 7542644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction by DNA immunization of a protective antitumor cytotoxic T lymphocyte response against a minimal-epitope-expressing tumor.
    Iwasaki A; Barber BH
    Cancer Immunol Immunother; 1998 Jan; 45(5):273-9. PubMed ID: 9439651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of spontaneous and interleukin-2-induced natural killer cell activity in the cytotoxicity and rejection of Fas+ and Fas- tumor cells.
    Bradley M; Zeytun A; Rafi-Janajreh A; Nagarkatti PS; Nagarkatti M
    Blood; 1998 Dec; 92(11):4248-55. PubMed ID: 9834230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumour-specific CTL response requiring interactions of four different cell types and recognition of MHC class I and class II restricted tumour antigens.
    Schirrmacher V; Schild HJ; Gückel B; von Hoegen P
    Immunol Cell Biol; 1993 Aug; 71 ( Pt 4)():311-26. PubMed ID: 7901150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of CD8+ cytotoxic T lymphocyte/tumor cell interactions reflecting recognition of an endogenously expressed murine wild-type p53 determinant.
    Hilburger Ryan M; Abrams SI
    Cancer Immunol Immunother; 2001 Jan; 49(11):603-12. PubMed ID: 11225991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.